Connect Biopharma Reports Positive Phase 1 Results for Rademikibart
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 17 hours ago
0mins
Should l Buy CNTB?
Source: NASDAQ.COM
- Clinical Trial Results: Connect Biopharma reported positive topline preliminary results from its Phase 1 clinical pharmacology study of intravenous rademikibart, where a 300 mg dose administered via a 2-minute IV push showed significantly faster FEV1 improvement compared to the previously tested 600 mg subcutaneous administration.
- FEV1 Improvement: Clinically important increases in FEV1 of 100 mL to over 400 mL were observed in many asthma and COPD patients as early as 15 minutes post-dosing, demonstrating the rapid efficacy of rademikibart.
- Sustained Effects: Patients receiving rademikibart maintained mean FEV1 improvements of approximately 200 to 400 mL from baseline through Day 29, indicating its potential for long-term efficacy in both asthma and COPD.
- Future Plans: The company expects to report topline data from the ongoing Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD by mid-2026 and plans to quickly engage with the FDA to align on a Phase 3 program.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CNTB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CNTB
Wall Street analysts forecast CNTB stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.450
Low
7.00
Averages
8.67
High
10.00
Current: 3.450
Low
7.00
Averages
8.67
High
10.00
About CNTB
Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company. The Company is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The Company has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CONNECT BIOPHARMA HOLDINGS LTD - RADEMIKIBART SHOWS GOOD TOLERABILITY AND SAFETY SIMILAR TO PLACEBO
Company Overview: Connect Biopharma Holdings Ltd is a biopharmaceutical company focused on developing therapies for autoimmune diseases.
Recent Developments: The company has been rated with safety comparable to other leading firms in the industry, indicating a strong focus on patient safety in its drug development processes.
See More
CONNECT BIOPHARMA HOLDINGS LTD - RADEMIKIBART SHOWS QUICK AND LONG-LASTING EFFECTIVENESS IN PHASE 3 STUDY FOR ATOPIC DERMATITIS OVER 52 WEEKS
Company Overview: Connect Biopharma Holdings Ltd. has achieved significant advancements in its clinical research.
Study Focus: The company’s Phase 3 study targets the treatment of atopic dermatitis, demonstrating rapid and durable efficacy.
Duration of Study: The clinical trial was conducted over a period of 52 weeks.
Implications: These results may enhance treatment options for patients suffering from atopic dermatitis.
See More
CONNECT Biopharma Reports Encouraging Preliminary Results from Phase 1 Trial of Intravenous Rademikibart in Asthma and COPD Patients
Positive Study Results: Connect Biopharma announced positive topline data from its Phase 1 study of intravenous (IV) RademiKibartin in patients with asthma or COPD.
Focus on Respiratory Conditions: The study highlights the potential of RademiKibartin as a treatment option for individuals suffering from respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD).
See More
Connect Biopharma Secures $20.2 Million in Private Placement
- Funding Scale and Purpose: Connect Biopharma has entered into a securities purchase agreement to sell 6.13 million shares at $3.25 each, anticipating gross proceeds of approximately $20.2 million, which will be utilized for R&D of clinical products and general corporate purposes, thereby enhancing the company's financial stability.
- Cash Flow Outlook: This financing is expected to extend the company's cash runway into the second half of 2027, ensuring sufficient operational funding in the coming years by combining it with existing cash and short-term investments, supporting ongoing R&D in inflammatory disease treatments.
- Investor Participation: The private placement is led by the company's largest investor, Panacea Venture, and includes participation from various new and existing U.S.-based healthcare investors, reflecting market confidence in Connect Biopharma's future growth and solidifying its position in the biopharmaceutical sector.
- Compliance and Registration Statement: The securities sold in this offering are not registered under the Securities Act of 1933, and Connect Biopharma has committed to filing a registration statement with the SEC within 45 days post-closing, ensuring compliance and paving the way for future securities trading.
See More
Connect Biopharma Reports Positive Clinical Data and Funding
- Clinical Trial Results: Connect Biopharma's Phase 1 study showed that a single 300 mg intravenous dose of Rademikibart led to rapid lung function improvements of over 200 mL in many asthma and COPD patients within 15 minutes, indicating the therapy's unique bronchodilator-like effects and potential for future treatments.
- Best-in-Class Efficacy: In the Phase 3 RADIANT-AD study conducted with Simcere, 96.6% of 259 patients with moderate-to-severe atopic dermatitis achieved EASI-75, 87.1% reached IGA 0/1, and 85.3% achieved EASI-90, demonstrating Rademikibart's significant potential for long-term disease control.
- Funding Plan: The company announced a $20.2 million private placement, selling 6,130,000 shares at $3.25 each, expected to close on March 31, 2026, with proceeds aimed at supporting clinical program development and general corporate purposes, ensuring operational funding into the second half of 2027.
- Stock Price Movement: CNTB's stock has traded between $0.51 and $3.82 over the past year, closing at $3.45 on Friday, with a pre-market increase of 13% to $3.88, reflecting strong market response to the company's positive announcements.
See More
Connect Biopharma Reports Positive Phase 1 Results for Rademikibart
- Clinical Trial Results: Connect Biopharma reported positive topline preliminary results from its Phase 1 clinical pharmacology study of intravenous rademikibart, where a 300 mg dose administered via a 2-minute IV push showed significantly faster FEV1 improvement compared to the previously tested 600 mg subcutaneous administration.
- FEV1 Improvement: Clinically important increases in FEV1 of 100 mL to over 400 mL were observed in many asthma and COPD patients as early as 15 minutes post-dosing, demonstrating the rapid efficacy of rademikibart.
- Sustained Effects: Patients receiving rademikibart maintained mean FEV1 improvements of approximately 200 to 400 mL from baseline through Day 29, indicating its potential for long-term efficacy in both asthma and COPD.
- Future Plans: The company expects to report topline data from the ongoing Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD by mid-2026 and plans to quickly engage with the FDA to align on a Phase 3 program.
See More
CONNECT BIOPHARMA HOLDINGS LTD - RADEMIKIBART SHOWS GOOD TOLERABILITY AND SAFETY SIMILAR TO PLACEBO
Company Overview: Connect Biopharma Holdings Ltd is a biopharmaceutical company focused on developing therapies for autoimmune diseases.
Recent Developments: The company has been rated with safety comparable to other leading firms in the industry, indicating a strong focus on patient safety in its drug development processes.
See More
CONNECT BIOPHARMA HOLDINGS LTD - RADEMIKIBART SHOWS QUICK AND LONG-LASTING EFFECTIVENESS IN PHASE 3 STUDY FOR ATOPIC DERMATITIS OVER 52 WEEKS
Company Overview: Connect Biopharma Holdings Ltd. has achieved significant advancements in its clinical research.
Study Focus: The company’s Phase 3 study targets the treatment of atopic dermatitis, demonstrating rapid and durable efficacy.
Duration of Study: The clinical trial was conducted over a period of 52 weeks.
Implications: These results may enhance treatment options for patients suffering from atopic dermatitis.
See More
CONNECT Biopharma Reports Encouraging Preliminary Results from Phase 1 Trial of Intravenous Rademikibart in Asthma and COPD Patients
Positive Study Results: Connect Biopharma announced positive topline data from its Phase 1 study of intravenous (IV) RademiKibartin in patients with asthma or COPD.
Focus on Respiratory Conditions: The study highlights the potential of RademiKibartin as a treatment option for individuals suffering from respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD).
See More
Connect Biopharma Secures $20.2 Million in Private Placement
- Funding Scale and Purpose: Connect Biopharma has entered into a securities purchase agreement to sell 6.13 million shares at $3.25 each, anticipating gross proceeds of approximately $20.2 million, which will be utilized for R&D of clinical products and general corporate purposes, thereby enhancing the company's financial stability.
- Cash Flow Outlook: This financing is expected to extend the company's cash runway into the second half of 2027, ensuring sufficient operational funding in the coming years by combining it with existing cash and short-term investments, supporting ongoing R&D in inflammatory disease treatments.
- Investor Participation: The private placement is led by the company's largest investor, Panacea Venture, and includes participation from various new and existing U.S.-based healthcare investors, reflecting market confidence in Connect Biopharma's future growth and solidifying its position in the biopharmaceutical sector.
- Compliance and Registration Statement: The securities sold in this offering are not registered under the Securities Act of 1933, and Connect Biopharma has committed to filing a registration statement with the SEC within 45 days post-closing, ensuring compliance and paving the way for future securities trading.
See More
Connect Biopharma Reports Positive Clinical Data and Funding
- Clinical Trial Results: Connect Biopharma's Phase 1 study showed that a single 300 mg intravenous dose of Rademikibart led to rapid lung function improvements of over 200 mL in many asthma and COPD patients within 15 minutes, indicating the therapy's unique bronchodilator-like effects and potential for future treatments.
- Best-in-Class Efficacy: In the Phase 3 RADIANT-AD study conducted with Simcere, 96.6% of 259 patients with moderate-to-severe atopic dermatitis achieved EASI-75, 87.1% reached IGA 0/1, and 85.3% achieved EASI-90, demonstrating Rademikibart's significant potential for long-term disease control.
- Funding Plan: The company announced a $20.2 million private placement, selling 6,130,000 shares at $3.25 each, expected to close on March 31, 2026, with proceeds aimed at supporting clinical program development and general corporate purposes, ensuring operational funding into the second half of 2027.
- Stock Price Movement: CNTB's stock has traded between $0.51 and $3.82 over the past year, closing at $3.45 on Friday, with a pre-market increase of 13% to $3.88, reflecting strong market response to the company's positive announcements.
See More
Connect Biopharma Reports Positive Phase 1 Results for Rademikibart
- Clinical Trial Results: Connect Biopharma reported positive topline preliminary results from its Phase 1 clinical pharmacology study of intravenous rademikibart, where a 300 mg dose administered via a 2-minute IV push showed significantly faster FEV1 improvement compared to the previously tested 600 mg subcutaneous administration.
- FEV1 Improvement: Clinically important increases in FEV1 of 100 mL to over 400 mL were observed in many asthma and COPD patients as early as 15 minutes post-dosing, demonstrating the rapid efficacy of rademikibart.
- Sustained Effects: Patients receiving rademikibart maintained mean FEV1 improvements of approximately 200 to 400 mL from baseline through Day 29, indicating its potential for long-term efficacy in both asthma and COPD.
- Future Plans: The company expects to report topline data from the ongoing Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD by mid-2026 and plans to quickly engage with the FDA to align on a Phase 3 program.
See More
